Spectral Diagnostics Inc. (Spectral) is focuses on the development and commercialization of a treatment for severe sepsis. The Company�s products include Endotoxin Activity Assay (EAA) and the Toraymyxin therapeutic (PMX) and Reagents. The Company also manufactures and sells certain proprietary reagents. Endotoxin Activity Assay has achieved United States Federal and Drug Administration (FDA), Health Canada and European CE clearance. PMX is a therapeutic hemoperfusion device that removes endotoxin from the bloodstream and the Company is conducting a Phase III clinical trial for the treatment of severe sepsis and septic shock. Spectral develops, produces and markets recombinant proteins, antibodies and calibrators.